Gabriel Krigsfeld

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating <i>PIK3CA</i> Alterations

Zachary S. Zumsteg, Natasha Morse, Gabriel Krigsfeld et al. · Clinical Cancer Research · 2015 · 78 citations · Full text

Medicine, Cancer Biology, Radiation Oncology +14

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with <i>TP53</i> aberrations: a pooled analysis from four clinical trials

John N. Allan, Tait D. Shanafelt, Adrian Wiestner et al. · British Journal of Haematology · 2021 · 64 citations · Full text

Medicine, Oncology, Pharmacology +12

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types

Gabriel Krigsfeld, Emily Prince, James Pratt et al. · Journal of Clinical Pathology · 2020 · 52 citations · Full text

Medicine, Oncology, Medical Oncology +14

Decreased<i>SMAD4</i>expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma

Haixia Cheng, Elana J. Fertig, Hiroyuki Ozawa et al. · Cancer Biology & Therapy · 2015 · 44 citations · Full text

Medicine, Molecular Biology, Oncology +17

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

Paolo Ghia, Carolyn Owen, John N. Allan et al. · HemaSphere · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16